112 related articles for article (PubMed ID: 15634011)
1. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.
Murugesan N; Gu Z; Fadnis L; Tellew JE; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Valentine MT; Humphreys WG; Lan SJ; Ewing WR; Carlson KE; Kowala MC; Zahler R; Macor JE
J Med Chem; 2005 Jan; 48(1):171-9. PubMed ID: 15634011
[TBL] [Abstract][Full Text] [Related]
2. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.
Murugesan N; Tellew JE; Gu Z; Kunst BL; Fadnis L; Cornelius LA; Baska RA; Yang Y; Beyer SM; Monshizadegan H; Dickinson KE; Panchal B; Valentine MT; Chong S; Morrison RA; Carlson KE; Powell JR; Moreland S; Barrish JC; Kowala MC; Macor JE
J Med Chem; 2002 Aug; 45(18):3829-35. PubMed ID: 12190306
[TBL] [Abstract][Full Text] [Related]
4. AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.
Cediel E; de Las Heras N; Sanz-Rosa D; Velasco O; Cachofeiro V; Lahera V
Kidney Int Suppl; 2005 Jan; (93):S3-9. PubMed ID: 15613065
[TBL] [Abstract][Full Text] [Related]
5. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
6. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC
J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Choung W; Jung HJ; Nam EH; Yang D; Yoo B; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim KH; Chin J; Jung K; Lee G; Kim SH
Bioorg Med Chem Lett; 2018 Oct; 28(19):3155-3160. PubMed ID: 30177375
[TBL] [Abstract][Full Text] [Related]
8. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
Murugesan N; Gu Z; Stein PD; Bisaha S; Spergel S; Girotra R; Lee VG; Lloyd J; Misra RN; Schmidt J; Mathur A; Stratton L; Kelly YF; Bird E; Waldron T; Liu EC; Zhang R; Lee H; Serafino R; Abboa-Offei B; Mathers P; Giancarli M; Seymour AA; Webb ML; Hunt JT
J Med Chem; 1998 Dec; 41(26):5198-218. PubMed ID: 9857090
[TBL] [Abstract][Full Text] [Related]
9. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and pharmacological evaluation of 5-oxo-1,2,4-oxadiazole derivatives as AT1 antagonists with antihypertension activities.
Zhu W; Bao X; Ren H; Liao P; Zhu W; Yan Y; Wang L; Chen Z
Clin Exp Hypertens; 2016; 38(5):435-42. PubMed ID: 27362285
[TBL] [Abstract][Full Text] [Related]
11. Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Yadav MR; Gandhi HP; Naik PP; Giridhar R
Pharm Biol; 2012 Apr; 50(4):439-42. PubMed ID: 22136253
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
[TBL] [Abstract][Full Text] [Related]
14. Integrative control of coronary resistance vessel tone by endothelin and angiotensin II is altered in swine with a recent myocardial infarction.
de Beer VJ; Sorop O; Pijnappels DA; Dekkers DH; Boomsma F; Lamers JM; Duncker DJ; Merkus D
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2069-77. PubMed ID: 18310517
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists.
Tellew JE; Baska RA; Beyer SM; Carlson KE; Cornelius LA; Fadnis L; Gu Z; Kunst BL; Kowala MC; Monshizadegan H; Murugesan N; Ryan CS; Valentine MT; Yang Y; Macor JE
Bioorg Med Chem Lett; 2003 Mar; 13(6):1093-6. PubMed ID: 12643919
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the AT(2)-receptor in angiotensin II-induced facilitation of sympathetic neurotransmission.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):181-7. PubMed ID: 12563569
[TBL] [Abstract][Full Text] [Related]
17. Discovery of losartan, the first angiotensin II receptor antagonist.
Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
Zhang J; Wang JL; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Bioorg Med Chem; 2012 Jul; 20(14):4208-16. PubMed ID: 22727371
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists.
Bao X; Zhu W; Yuan W; Zhu X; Yan Y; Tang H; Chen Z
Eur J Med Chem; 2016 Nov; 123():115-127. PubMed ID: 27474928
[TBL] [Abstract][Full Text] [Related]
20. Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Rossi GP; Cavallin M; Belloni AS; Mazzocchi G; Nussdorfer GG; Pessina AC; Sartore S
Cardiovasc Res; 2002 Jul; 55(1):178-89. PubMed ID: 12062721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
